Department of Nuclear Medicine, University Hospital Münster, Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany; West German Cancer Center (WTZ); German Cancer Consortium (DKTK).
Department of Nuclear Medicine, University Hospital, Inselspital Bern, Bern, Switzerland.
PET Clin. 2021 Jul;16(3):391-396. doi: 10.1016/j.cpet.2021.03.004.
Prostate-specific membrane antigen (PSMA) has been the subject of numerous studies within the last 3 decades. PSMA-targeted imaging and therapy have significantly changed the management of patients with prostate cancer in various disease stages, especially in advanced metastasized castration-resistant prostate cancer. Lutetium-177-conjugated PSMA-617 or PSMA-I&T (Lu-PSMA) has shown promising results in multicenter retrospective and monocenter prospective trials. The aim of this review is to provide an overview of the history and current and future developments of PSMA-targeted therapy. A special focus of this review is on PSMA PET-guided management of patients receiving PSMA-targeted radioligand therapy.
前列腺特异性膜抗原（PSMA）在过去 30 年中一直是许多研究的主题。PSMA 靶向成像和治疗在不同疾病阶段的前列腺癌患者的管理中发生了重大变化，尤其是在晚期转移性去势抵抗性前列腺癌中。镥-177 结合的 PSMA-617 或 PSMA-I&T（Lu-PSMA）在多中心回顾性和单中心前瞻性试验中显示出有前途的结果。本综述的目的是提供 PSMA 靶向治疗的历史和现状以及未来发展的概述。本综述的一个特别重点是 PSMA PET 引导下接受 PSMA 靶向放射性配体治疗的患者的管理。
